Clinical Trials · NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 12,800
- Start date
- Jul 2025
- Locations
- 782 sites, 36 countries
- Primary endpoint
- Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])